Transforming lives through a healthy microbiome.

Richard Laube

Executive Chairman of the Board, Co-Founder

MA from Boston University in Evaluation Research and Social Psychology. 40 years of experience in building brands and businesses:

• 19 years at Procter & Gamble from Brand Management to General Management.
• 6 years at Roche Pharmaceuticals as CEO Roche Consumer Health.
• 5 years at Nestle SA as CEO Nestle Nutrition.
• 5 years at Nobel Biocare AG as CEO.
• 5 years at Gnubiotics as Executive Chairman.
• Board positions include; Logitech, Atkins/Simply Good Foods Company, Glanbia, Piqur Therapeutics.

$12 Billion in deal transaction experience, buying, selling & integrating businesses.

Richard has been a successful business leader building brands and businesses at five global companies for 35 years. Upon his retirement in 2016, Richard joined the founders of Gnubiotics for his "second" career with the ambition of realizing the full potential of Gnubiotics' breakthrough science to deliver its health and healing potential for the microbiome of humans and pets. In his spare time, Richard is an avid athlete having won multiple New England 200 meter and sprint relay championships while at Boston University, followed by competing in skiing, long distance running and triathlons during his professional career. Lastly, Richard has taken up golf at the age of 60 (Hcp 16). Richard has raised 4 generations of Bernese Mountain Dogs named Centa, Kuma, Nicky and Minha.

Yemi Adesokan, PhD

CEO, CSO, Co-Founder, Board Member

• PhD University of California -Irvine – Physical Chemistry
• Postdoctoral -Fellowship: Harvard Medical School – Genetics
• MIT -TR 35 Global Innovator
• Boston Business Journal 40 under 40

Yemi Adesokan is an award-winning scientist, entrepreneur and biotech executive with a track record in technology innovation, product and business development, as well as team and portfolio management. Yemi has worked as a strategic consultant to leading pharmaceutical companies. In a strategic advisor role to a pharmaceutical company with over $25Billion in sales, he helped launch and manage the life cycle of a drug with annual peak sales of $1.5Billion. Yemi has been recognized globally for his work with awards, including the Boston Business Journal 40 under 40 award and the MIT Technology Review’s annual list of 35 top global innovators MIT TR35. He holds a PhD in Chemistry from the University of California, Irvine and completed a post-doctoral appointment in genetics at Harvard Medical School with George Church. In his spare time, Yemi serves as a Trustee of the American School of Madrid (ASM), Spain, where he remains committed to instilling a passion for science in the next generation. Yemi loves travelling and watching NCAA basketball. His three daughters have a cat named Tiger with hopefully the best microbiome of all felines.

Bernardo Horta E Costa

CFO, Co-Founder, Board Member

• Altium Capital
• Haitong Bank – M&A
• EDP Renewables
• PWC
• BA Universidade Católica Portuguesa

Prior to co-founding Gnubiotics, Bernardo worked as an investment banker for Altium Capital and Haitong Bank. He advised both on buy and sell side transactions in several sectors including TMT, Agribusiness, Chemicals, and IT totaling over $1 billion. Prior to investment banking, Bernardo worked in project financing at EDP Renewables, a leading renewable energy company, where he helped structure financing for wind farms in Romania with a total financing value of EUR 188 million. Bernardo also worked at PWC as a strategy consultant and an auditor. Bernardo enjoys many sports from sailing, golfing and skiing to Argentine padel ball. He enjoys travelling and experiencing different cultures and is the proud pet parent of labradors.

James Rothman, PhD

Senior Advisor

• The Nobel Prize in Physiology or Medicine 2013
• The Kavli Prize for Neuroscience
• The E.B. Wilson Medal
• Chair of the Department of Cell Biology at Yale University

Prof. James Rothman is one of the world's most distinguished biochemists. He was awarded the Nobel Prize in Physiology or Medicine in 2013 for his work in the field of vesicle trafficking, which revolutionized our understanding of how cells are organized and how they form and secrete glycoproteins. He previously served as Vice Chairman of the Sloan-Kettering Institute for Cancer Research, as Chief Science Officer of GE Healthcare, and as senior advisor to R&D leadership at several biopharma companies, most recently GSK and Eli Lilly.

John Baldoni, PhD

Senior Advisor

• Ph.D. from Penn State University in biological chemistry
• Senior Vice President of Platform Technology and Science on GSK’s R&D Executive Team

John Baldoni is a renowned drug discovery and development expert, with extensive experience in all aspects of drug development, from basic research to scale up and market authorization. He served as the Senior Vice President of Platform Technology and Science on GSK’s R&D Executive Team. He also headed an innovative AI-drive drug discovery unit. Mr. Baldoni brings a wealth of knowledge and experience to Gnubiotics, and his expertise will be invaluable in helping the company achieve its goals.